Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients

Detalles Bibliográficos
Autores principales: Martin, Adriana, Schellenberg, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Meeting Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487820/
http://dx.doi.org/10.1186/1710-1492-8-S1-A19
_version_ 1782248522965319680
author Martin, Adriana
Schellenberg, Robert
author_facet Martin, Adriana
Schellenberg, Robert
author_sort Martin, Adriana
collection PubMed
description
format Online
Article
Text
id pubmed-3487820
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34878202012-11-08 Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients Martin, Adriana Schellenberg, Robert Allergy Asthma Clin Immunol Meeting Abstract BioMed Central 2012-11-02 /pmc/articles/PMC3487820/ http://dx.doi.org/10.1186/1710-1492-8-S1-A19 Text en Copyright ©2012 Martin and Schellenberg; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Meeting Abstract
Martin, Adriana
Schellenberg, Robert
Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
title Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
title_full Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
title_fullStr Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
title_full_unstemmed Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
title_short Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
title_sort evaluation of safety and efficacy of a 20% subcutaneous immunoglobulin (hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
topic Meeting Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487820/
http://dx.doi.org/10.1186/1710-1492-8-S1-A19
work_keys_str_mv AT martinadriana evaluationofsafetyandefficacyofa20subcutaneousimmunoglobulinhizentraafteradoseequivalentswitchfromintravenousorsubcutaneousreplacementtherapyinacohortofprimaryimmunodeficientpatients
AT schellenbergrobert evaluationofsafetyandefficacyofa20subcutaneousimmunoglobulinhizentraafteradoseequivalentswitchfromintravenousorsubcutaneousreplacementtherapyinacohortofprimaryimmunodeficientpatients

Ejemplares similares